Sanara MedTech (SMTI) Q4 2025 Earnings Transcript

Sanara MedTech reported record 2025 net revenue of $103.1 million, up 19% year over year and above the $100 million mark for the first time, while full-year gross margin held at 93% and adjusted EBITDA improved to $17 million. Q4 net revenue rose 5% to $27.5 million, or 13% excluding prior-year hurricane-related BIASURGE sales, but net income was pressured by a $1.8 million IP impairment and higher interest expense. Management reaffirmed 2026 guidance of $116 million to $121 million in revenue, highlighted the Vizient contract for BIASURGE, and said OsStic remains on track for a Q1 2027 launch.

Analysis

SMTI is transitioning from a story-stock into a compounding operating business, but the market is likely still underestimating how much of 2026 upside can come from distribution density rather than new product launches. The key second-order effect is that the Vizient win should improve rep velocity inside already-contracted accounts, which can compress the usual adoption lag and create a cleaner earnings revision cycle over the next 2-3 quarters. That matters because the company is finally showing enough gross margin and cash generation to fund growth internally, reducing the need for dilutive capital raises.

The main near-term risk is not demand, but expense drift. Management is intentionally stepping up sales coverage and R&D while debt has already crept higher, so any miss on conversion of the newly expanded distributor base could turn into a margin reset rather than a growth acceleration. The noncash impairment is less important than the signal it sends: the company is pruning legacy optionality and concentrating risk into a narrower surgical thesis, which makes execution quality much more visible from here.

Contrary to the headline optimism, the real valuation driver may be 2027 pre-launch positioning for OsStic rather than 2026 revenue alone. If the market starts to believe OsStic is a credible category-creating product, SMTI could re-rate on a multi-year TAM expansion story; if regulatory or commercial timelines slip, the stock is vulnerable because the current setup already bakes in steady double-digit growth. In the meantime, the cleanest bull case is a quarterly cadence of modest beats plus improving cash flow, not a single catalyst event.

Key Decisions for Investors

• Long SMTI on pullbacks over the next 1-4 weeks: the setup favors a gradual re-rating as Vizient access converts into utilization, with upside to 2026 revenue revisions if facility penetration accelerates faster than management's conservative guide.
• Buy SMTI Jan-2027 or Jan-2028 call spreads rather than outright calls: this expresses the OsStic optionality with limited premium burn, and the payoff improves if investors start capitalizing the pipeline earlier than 2027 launch.
• Pair trade: long SMTI / short a lower-growth surgical consumables peer with weaker gross margin leverage and no visible pipeline catalyst over the next 6-12 months; SMTI has better self-funded growth and a cleaner re-rating path if execution holds.
• If SMTI rallies sharply on early 2026 channel checks, take partial profits into the move: the near-term risk is a classic distribution-to-revenue timing gap, and the stock can overshoot before the broader facility rollout is visible in reported numbers.
• Avoid adding aggressively ahead of Q1 2026 results unless channel data confirms the Vizient contract is translating into orders; the highest risk window is a 'great pipeline, modest bookings' quarter that could compress multiple on expense guidance.